Hormonal Therapy of Cryptorchidism with Human Chorionic Gonadotropin(HCG)

Job, J C; Canlorbe, P; Garagorri, Jesus-Maria; Toublanc, Jean-Edmond

doi:10.1016/s0094-0143(21)01355-0

Cited by 39 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parenteral hCG presumably works by stimulating the Leydig cells to produce testosterone, and then descent of the testis is induced by testosterone or its 5α‐reduced form, DHT. However, the results of hCG therapy suffer from the nagging doubt regarding the exclusion of retractile testes, and success rates ranging from 6% to around 40% have been reported 39 , 46 , 47 …”

Section: Endocrinology: Clinically Useful?mentioning

confidence: 99%

Scientific Basis of Testicular Descent and Management Implications for Cryptorchidism

1994

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY Cryptorchidism occurs in about 1% of boys, but has a raised incidence in those with deficiencies of androgen function. Greater knowledge of fetal‐maternal endocrinology and related experimental work has provided evidence that fetal testicular endocrine function is vital in descent of the gonad. The therapeutic use of hCG has, however, been disappointing, and its role is confined to helping to distinguish the retractile from the undescended testis. Cryptorchidism is commonly associated with congenital pathological defects such as ductal abnormalities, and others (including interstitial fibrosis and a reduction in germ cells) develop after 1‐2 years, while later these patients are at greater risk of carcinoma in situ and germ cell cancer. The demonstration of the early pathological changes has recently dictated much earlier surgical correction, but long‐term follow‐up is needed to prove clinical benefit from this practice.

show abstract

Section: Endocrinology: Clinically Useful?mentioning

confidence: 99%